HPV Genotype Distribution and Associated Factors Among HPV-DNA-Positive Women at University Medical Center Ho Chi Minh City, 2025
Main Article Content
Abstract
A study was conducted on 390 women with positive HPV-DNA test results at the University Medical Center Ho Chi Minh City - Branch 2 in 2025 to investigate the distribution of HPV genotypes and associated factors. The results showed that HPV-52 was the most prevalent genotype (39.0%), followed by HPV-16 (22.3%) and HPV-58 (21.3%). Multiple infections (≥ 2 genotypes) accounted for 35.1% of cases, and 77.2% of participants had never received HPV vaccination. The proportion of unvaccinated individuals was 77.2%. The rate of unvaccinated women in the study population was high (77.2%), while demographic factors and vaccination history did not demonstrate a statistically significant protective association due to sample size limitations. Other factors, such as marital status or completion of the 3-dose vaccine series, did not show statistically significant associations in this study. The high prevalence of non-16/18 HPV genotypes highlights the need to consider implementing extended HPV genotyping in screening strategies that align with local epidemiological characteristics.
Article Details
Keywords
Human papillomavirus, genotype distribution, HPV-52, HPV-58, cervical cancer screening, HPV vaccine, Vietnam
References
2. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020. ISBN 978-92-4-001410-7.
3. Wei F, Georges D, Man I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024; 404(10451): 435-444.
4. Osmani V, Rossiter M, Hörner L, et al. Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology: a systematic review and meta-analysis. BMJ Glob Health. 2025; 10(4): e017309. Published 2025 Apr 2.
5. Aldossary MS, Mufrrih M, El Dalatony MM, et al. Prevalence and genotypes’ distribution of human papillomavirus among women in Saudi Arabia: a systematic review and meta-analysis. Front Public Health. 2025; 13: 1580699. Published 2025 May 15.
6. Han S, Lin M, Liu M, et al. Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases. BMC Med. 2025; 23: 158.
7. Wang M, Liang H, Yan Y, et al. Distribution of HPV types among women with HPV-related diseases and exploration of lineages and variants of HPV 52 and 58 among HPV-infected patients in China: A systematic literature review. Human Vaccines & Immunotherapeutics. 2024; 20(1).
8. Nguyet HM, Phan TT, Quach KU, et al. Prevalence and genotype distribution of high-risk human papillomavirus infection among Vietnamese women in Ho Chi Minh City, Viet Nam: a population-based cross-sectional study. Gynecol Oncol Rep. 2024; 56: 101526.
9. International Agency for Research on Cancer (IARC). GLOBOCAN 2022: Viet Nam Fact Sheet. Global Cancer Observatory. Version 1.1 (08 Feb 2024).
10. Nguyet HM, Tam PT, Ung QK, et al. Prevalence and genotype distribution of high-risk Human Papillomavirus infection among Vietnamese women in Ho Chi Minh City, Viet Nam: A population-based cross-sectional study. Gynecol Oncol Rep. 2024 Oct 9; 56: 101526.
11. Ueda Y. Epidemiology of cervical cancer and HPV infection in Asia and Oceania. J Obstet Gynaecol Res. 2024; 50(Suppl 1): 31-41.
12. Nam LV, Son HX, Bang LVN, et al. HPV prevalence and genotype distribution among Vietnamese cervical cancer patients in the northern region of Vietnam, from 2018 - 2020. J Clin Virol Plus. 2024; 4(2): 100182.
13. Faizo AAA, Bellward C, Hernandez-Lopez HR, et al. The splicing factor kinase, SR protein kinase 1 (SRPK1) is essential for late events in the human papillomavirus life cycle. PLoS Pathog. 2025; 21(4): e1012697.
14. Pham QD, Prem K, Le TA, et al. Prevalence and risk factors for human papillomavirus infection among female sex workers in Hanoi and Ho Chi Minh City, Viet Nam: a cross-sectional study. Western Pac Surveill Response J. 2022; 13(4): 1-11. doi:10.5365/wpsar.2022.13.4.894.
15. World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022; 97(50): 645-672.